Tenofovir Disoproxil Fumarate Reduces the Severity of COVID‐19 in Patients with Chronic Hepatitis B

Background and Aims HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV). Meth...

Descripción completa

Detalles Bibliográficos
Autores: Mateos‐Muñoz, B, Bañares Cañizares, Rafael, Moreno Guillén, Santiago, Albillos, A
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/126400
Acceso en línea:https://hdl.handle.net/20.500.14352/126400
Access Level:acceso abierto
Palabra clave:616.36-002
Hepatitis B
COVID-19
Tenofovir
Entecavir
Gastroenterología y hepatología
3205.03 Gastroenterología
id ES_3bbc53f1cbc37ae3bbcbfb1d44e5948c
oai_identifier_str oai:docta.ucm.es:20.500.14352/126400
network_acronym_str ES
network_name_str España
repository_id_str
spelling Tenofovir Disoproxil Fumarate Reduces the Severity of COVID‐19 in Patients with Chronic Hepatitis BMateos‐Muñoz, BBañares Cañizares, RafaelMoreno Guillén, SantiagoAlbillos, A616.36-002Hepatitis BCOVID-19TenofovirEntecavirGastroenterología y hepatología3205.03 GastroenterologíaBackground and Aims HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV). Methods Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19. Results Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04–0.67, p = 0.01). Conclusion Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered.Springer Nature LinkUniversidad Complutense de Madrid20232023-02-0320232023-02-03journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/126400reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1264002026-06-02T12:44:21Z
dc.title.none.fl_str_mv Tenofovir Disoproxil Fumarate Reduces the Severity of COVID‐19 in Patients with Chronic Hepatitis B
title Tenofovir Disoproxil Fumarate Reduces the Severity of COVID‐19 in Patients with Chronic Hepatitis B
spellingShingle Tenofovir Disoproxil Fumarate Reduces the Severity of COVID‐19 in Patients with Chronic Hepatitis B
Mateos‐Muñoz, B
616.36-002
Hepatitis B
COVID-19
Tenofovir
Entecavir
Gastroenterología y hepatología
3205.03 Gastroenterología
title_short Tenofovir Disoproxil Fumarate Reduces the Severity of COVID‐19 in Patients with Chronic Hepatitis B
title_full Tenofovir Disoproxil Fumarate Reduces the Severity of COVID‐19 in Patients with Chronic Hepatitis B
title_fullStr Tenofovir Disoproxil Fumarate Reduces the Severity of COVID‐19 in Patients with Chronic Hepatitis B
title_full_unstemmed Tenofovir Disoproxil Fumarate Reduces the Severity of COVID‐19 in Patients with Chronic Hepatitis B
title_sort Tenofovir Disoproxil Fumarate Reduces the Severity of COVID‐19 in Patients with Chronic Hepatitis B
dc.creator.none.fl_str_mv Mateos‐Muñoz, B
Bañares Cañizares, Rafael
Moreno Guillén, Santiago
Albillos, A
author Mateos‐Muñoz, B
author_facet Mateos‐Muñoz, B
Bañares Cañizares, Rafael
Moreno Guillén, Santiago
Albillos, A
author_role author
author2 Bañares Cañizares, Rafael
Moreno Guillén, Santiago
Albillos, A
author2_role author
author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv 616.36-002
Hepatitis B
COVID-19
Tenofovir
Entecavir
Gastroenterología y hepatología
3205.03 Gastroenterología
topic 616.36-002
Hepatitis B
COVID-19
Tenofovir
Entecavir
Gastroenterología y hepatología
3205.03 Gastroenterología
description Background and Aims HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV). Methods Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19. Results Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04–0.67, p = 0.01). Conclusion Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-02-03
2023
2023-02-03
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/126400
url https://hdl.handle.net/20.500.14352/126400
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature Link
publisher.none.fl_str_mv Springer Nature Link
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406324918321152
score 15,81155

Similares en LA Referencia